End of Zepbound Shortage Threatens $1 Billion Knockoff Weight-Loss Shot Industry
Americans who turned to telehealth companies and compounding pharmacies for cheap versions of Eli Lilly & Co.’s weight-loss ...
Hosted on MSN21h
Pharma Stock Roundup: FDA Approves SNY's Dupixent for COPD & More
This week, the FDA granted approval to Sanofi SNY and Regeneron’s REGN blockbuster drug, Dupixent, for its sixth indication.
Lilly Medicine Foundry boosts company's investment in Lebanon to $13 billion
Eli Lilly and Co. announced Wednesday that it will boost its investment in Lebanon to more than $13 billion. The move increases Lilly's capital commitment in the United States to more than $23 billion ...
ConsumerAffairs23h
Texas sues drug companies and pharmacy benefit managers over insulin prices
The state of Texas has filed a lawsuit against drug companies that produce insulin and pharmacy benefit managers (PBM), claiming there is a conspiracy to k ...
Hims & Hers Health Asserts Demand For Its Compounded Weight Loss Offering To Continue Despite Resolved Supply Shortages
The FDA has resolved Eli Lilly's tirzepatide shortage, but localized supply issues persist. Meanwhile, Hims & Hers Health's ...